• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Titan Medical Inc.

    4/23/21 9:25:13 PM ET
    $TMDI
    Get the next $TMDI alert in real time by email
    S-8 1 a52413818.htm TITAN MEDICAL INC. S-8


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    FORM S-8  
    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

    Titan Medical Inc.
    (Exact name of registrant as specified in its charter)
     
       
    Ontario, Canada
    98-0663504
    (State or other jurisdiction of
    (I.R.S. Employer Identification No.)
    incorporation or organization)
     
    155 University Avenue, Suite 750
    Toronto, Ontario M5H 3B7
    Canada
    (Address of principal executive offices)

    TITAN MEDICAL INC. STOCK OPTION PLAN (AMENDED AND RESTATED EFFECTIVE AS OF OCTOBER 20, 2020)
    TITAN MEDICAL INC. DEFERRED SHARE UNIT PLAN
    TITAN MEDICAL INC. SHARE UNIT PLAN
    (Full title of plan)

    C T Corporation System
    1015 15th Street N.W., Suite 1000
    Washington, DC 20005
    (Name and address of agent for service)
     (202)572-3100
    (Telephone number, including area code, of agent for service)

    Copies to:


    Dorsey & Whitney LLP
    James Guttman
    Richard Raymer
    TD Canada Trust Tower
    Brookfield Place
    161 Bay Street, Suite 4310
    Toronto, Ontario Canada M5J 2S1
    (416) 367-7376

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

    Large Accelerated Filer [ ]
    Accelerated Filer []
    Non-Accelerated Filer [X]
    Smaller Reporting Company []
    Emerging Growth Company [X]
     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. [ ]

    CALCULATION OF REGISTRATION FEE
             
    Title of Each Class of
    Securities to be Registered
    Amount to
    be Registered(1)
    Proposed Maximum
    Offering Price Per
    Share(3)
    Proposed Maximum
    Aggregate Offering
    Price
    Amount of
    Registration Fee(2)(3)
    Common shares, no par value, issuable (i) under the Titan Medical Inc. Stock Option Plan, as amended and restated effective as of October 20, 2020; (ii) upon exercise or settlement of awards granted under the Titan Medical Inc. Deferred Share Unit Plan effective as of May 29, 2019; and (iii) upon exercise or settlement of awards granted under the Titan Medical Inc. Share Unit Plan, as amended as of February 16, 2021(2)
    4,781,515
    $1.50
    $7,172,272.50
    $782.49

       
    (1)
    Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers any additional securities that may be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions in accordance with the provisions of the plans.

    (2)
    Represents additional common shares of Titan Medical Inc. issuable (i) upon exercise of options under the Titan Medical Inc. Stock Option Plan, as amended and restated effective as of October 20, 2020; (ii) upon exercise or settlement of awards granted under the Titan Medical Inc. Deferred Share Unit Plan effective as of May 29, 2019; and (iii) upon exercise or settlement of awards granted under the Titan Medical Inc. Share Unit Plan, as amended as of February 16, 2021.

    (3)
    The proposed maximum offering price per share and the registration fee were calculated in accordance with Rule 457(c) and (h) based on the average high and low prices for the common shares of Titan Medical Inc. on April 20, 2021, as quoted on the NASDAQ Capital Market.

    EXPLANATORY NOTE

    This registration statement on Form S-8 (the “Registration Statement”) is being filed for the purpose of registering an additional 4,781,515 common shares (the “Common Shares”) of Titan Medical Inc. (the “Registrant” or “Company”) for issuance pursuant to (i) the exercise of options under the Titan Medical Inc. Stock Option Plan, as amended and restated effective as of October 20, 2020 (the “Stock Option Plan”), (ii) the exercise or settlement of awards granted under the Titan Medical Inc. Deferred Share Unit Plan effective as of May 29, 2019 (the “DSU Plan”), and (iii) the exercise or settlement of awards granted under the Titan Medical Inc. Share Unit Plan, as amended as of February 16, 2021 (the “SU Plan”).

    On July 22, 2020, the Registrant filed a registration statement on Form S-8 (File No. 333-240018) to register 9,455,713 Common Shares of the Registrant issuable (i) upon exercise of options under the Titan Medical Inc. Stock Option Plan, as amended and restated effective as of July 15, 2020, (ii) upon exercise or settlement of awards granted under the DSU Plan, and (iii) upon exercise or settlement of awards granted under the Titan Medical Inc. Share Unit Plan effective as of May 29, 2019.

    On October 20, 2020, the Registrant’s board of directors adopted amendments to the Stock Option Plan to remove provisions relating to incentive stock options qualified under Section 422 of the United States Internal Revenue Code that were not approved by the shareholders of the Registrant.

    On February 16, 2021, the Registrant’s board of directors adopted amendments to the SU Plan (i) to allow the grant of restricted share units and dividend restricted share units to non-employee directors of the Company, (ii) to permit non-employee directors of the Company to elect to receive the cash component of their compensation in restricted share units and (iii) to permit the Company to make such arrangements as the Company deems appropriate for the settlement of outstanding awards in the event of a change of control of the Company. 

    The contents of the Registrant’s registration statements on Form S-8 (File Nos. 333-240018 and 333-229612) are incorporated by reference herein.

    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1. Plan Information

    Information required by Part I to be contained in the Section 10(a) prospectus is omitted from the Registration Statement in accordance with Rule 428 under the Act and Note 1 to Part I of Form S-8.

    Item 2. Registrant Information and Employee Plan Annual Information


    Information required by Part I to be contained in the Section 10(a) prospectus is omitted from the Registration Statement in accordance with Rule 428 under the Act and Note 1 to Part I of Form S-8.

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation Of Documents By Reference.

    The following documents which have been and will in the future be filed by the Registrant with the United States Securities and Exchange Commission (the “SEC”) are incorporated into this Registration Statement by reference:

     
    (a)
    Our Annual Report on Form 40-F for the year ended December 31, 2020, filed with the SEC on April 1, 2021;
     
     
    (b)
    All other reports filed by the Registrant under Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) since December 31, 2020.
     
     
     
     
    (c)
    The description of the Common Shares contained in our Registration Statement on Form 40-F, as filed with the SEC on June 11, 2018, including any amendment or report filed for the purpose of amending such description.

    In addition, all reports and documents filed by us under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities being offered have been sold or which deregisters all securities then remaining unsold, and any Form 6-K furnished by us during such period or portions thereof that are identified in such Form 6-K as being incorporated by reference into this Registration Statement, shall be deemed to be incorporated by reference in and to be part of this Registration Statement from the date of filing of each such document.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    None.

    Item 6. Indemnification of Directors and Officers.

    Under the Business Corporation Act (Ontario) (the “OBCA”), the Registrant may indemnify a director or officer, a former director or officer or another individual who acts or acted at the Registrant’s request as a director or officer, or an individual acting in a similar capacity, of another entity, against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal, administrative, investigative or other proceeding in which the individual is involved because of that association with the Registrant or other entity on condition that (i) the individual acted honestly and in good faith with a view to the best interests of the Registrant or, as the case may be, to the best interests of the other entity for which the individual acted as a director or officer or in a similar capacity at the Registrant’s request, and (ii) in the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, the individual had reasonable grounds for believing that his conduct was lawful.  Further, the Registrant may, with court approval, indemnify a person described above in respect of an action by or on behalf of the Registrant or other entity to obtain a judgment in its favor, to which the individual is made a party because of the individual’s association with the Registrant or other entity, against all costs, charges and expenses reasonably incurred by the individual in connection with such action if the individual fulfills condition (i) above.  Additionally, the Registrant may advance money to a director, officer or other individual for the costs, charges, and expenses of a proceeding referred to above, with the necessary court approval where noted, but the individual is required to repay the money to the Registrant if the individual does not satisfy condition (i) above.  An individual described above is also entitled to indemnification as described above from the Registrant as a matter of right if the individual was not judged by a court or other competent authority to have committed any fault or omitted to do anything the individual ought to have done, and he fulfills conditions (i) and (ii) above.  The Registrant has entered into an indemnity agreement with each of its directors under which the Registrant has agreed to indemnify the individual in substantially the same circumstances as outlined in this paragraph.

    In accordance with the OBCA, the by-laws of the Registrant provide that the Registrant shall indemnify a director or officer, a former director or officer, or an individual who acts or acted at the Registrant's request as a director or officer, or an individual acting in a similar capacity, of another entity, and such person's heirs and legal representatives, against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal, administrative, investigative or other proceeding in which the individual is involved because of that association with the Registrant or other entity, provided that (i) the individual acted honestly and in good faith with a view to the best interests of the Registrant or, as the case may be, to the best interest of the other entity for which the individual acted as a director or officer or in a similar capacity at the Registrant’s request; and (ii) in the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, the person had reasonable grounds for believing that the individual's conduct was lawful.

    A policy of directors' and officers' liability insurance is maintained by the Registrant, at its expense, which insures directors and officers for losses as a result of claims against the directors and officers of the Registrant in their capacity as directors and officers.

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Registrant pursuant to the foregoing provisions, the Registrant has been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

    Item 7.
    Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    Number
    Exhibit
    4.1
    Titan Medical Inc. Stock Option Plan (Amended and Restated effective as of October 20, 2020) (incorporated by reference from Exhibit 99.1 to the Company’s Form 6-K filed on April 16, 2021)
    4.2
    Titan Medical Inc. Deferred Share Unit Plan (incorporated by reference from Exhibit 99.3 to the Company’s Form 6-K filed on April 16, 2021)
    4.3
    Titan Medical Inc. Share Unit Plan (amended as of February 16, 2021) (incorporated by reference from Exhibit 99.2 to the Company’s Form 6-K filed on April 16, 2021)
    5.1
    Opinion of Borden Ladner Gervais LLP
    23.1
    Consent of Borden Ladner Gervais LLP (Included in Exhibit 5.1)
    23.2
    Consent of BDO Canada LLP, Chartered Professional Accountants and Licensed Public Accountants
    24.1
    Power of Attorney (See Signature Pages)

    Item 9. Undertakings.

    (a)       The Registrant hereby undertakes:
     
    (1)       To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
     
    (i)      To include any prospectus required by section 10(a)(3) of the Securities Act; 
     
    (ii)     To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment hereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement;
     
    (iii)    To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;
      
    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference into this Registration Statement.
     
    (2)      That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
     
    (3)       To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
      
    (b)      The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c)       Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in such Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

    SIGNATURES
    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Toronto, Province of Ontario, Canada on April 23, 2021.




      TITAN MEDICAL INC.
       
      /s/ Monique L. Delorme

    Name:  Monique L. Delorme

    Title:    Chief Financial Officer
     
      (Principal Financial Officer)



    POWER OF ATTORNEY
    Each person whose signature appears below constitutes and appoints David McNally and Monique L. Delorme as his attorney-in-fact, with the power of substitution, for them in any and all capacities, to sign any amendments to this Registration Statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact, or their substitute or substitutes, may do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

           
    Signature
     
    Title
    Date
     
     
     
     
    /s/ David McNally
     
    President, Chief Executive Officer and Chairman
    April 23, 2021
    David McNally
     
    (Principal Executive Officer)
     
     
     
     
     
    /s/ Monique L. Delorme
     
    Chief Financial Officer
    April 23, 2021
    Monique L. Delorme
     
    (Principal Financial Officer)
     
     
     
     
     
    /s/ Paul Cataford
     
    Director
    April 23, 2021
    Paul Cataford
     
     
     
     
     
     
     
    /s/ Anthony J. Giovinazzo
     
    Director
    April 23, 2021
    Anthony J. Giovinazzo
     
     
     
     
     
     
     
    /s/ Cary G. Vance
     
    Director
    April 23, 2021
    Cary G. Vance
     
     
     
     
     
     
     
    /s/ Stephen Randall
     
    Director
    April 23, 2021
    Stephen Randall
     
     
     
     
     
     
     

    AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

           
    /s/ David McNally
     
    Authorized Representative
    April 23, 2021
    David McNally
     
    in the United States
     

    Get the next $TMDI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TMDI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TMDI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Titan Medical with a new price target

    Oppenheimer initiated coverage of Titan Medical with a rating of Outperform and set a new price target of $4.00

    4/7/21 6:31:59 AM ET
    $TMDI

    $TMDI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Titan Medical Announces Decision of Nasdaq Hearings Panel to Delist Common Shares

    TORONTO, ON, March 09, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (the "Company" or "Titan") (NASDAQ:TMDI, TSX:TMD) today announced that it has received a decision of the Nasdaq Hearings Panel (the "Panel") advising the Company that effective at the open of business on March 10, 2023, the Company's common shares will be delisted from The Nasdaq Stock Market ("Nasdaq"). On December 30, 2021, Nasdaq Listing Qualifications staff ("Staff") issued the Company a deficiency notice citing its failure to comply with the minimum bid price requirement under Listing Rule 5550(a)(2) (the "Rule"). In accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until June

    3/9/23 7:30:00 AM ET
    $TMDI

    Titan Medical Announces Executive Leadership Updates and Receipt of Nasdaq Notification Regarding Audit Committee Requirements

    Toronto, Ontario, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (the "Company" or "Titan") (NASDAQ:TMDI, TSX:TMD) today announced senior leadership changes and the receipt of a notification from the Nasdaq Stock Market LLC Listing Qualifications Department stating that following the resignation of Heather Knight from the Company's board of directors and audit committee, the Company no longer complies with Nasdaq's audit committee requirement set forth in Nasdaq Rule 5605. Senior Leadership Changes Following the announcement of February 8, 2023, the Company has decided to layoff certain members of the Company's senior leadership team. Each of these individuals remain available to a

    2/14/23 7:30:00 AM ET
    $TMDI

    Titan Medical Provides Corporate Update

    TORONTO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (the "Company" or "Titan") (NASDAQ:TMDI, TSX:TMD) today provided an update on the previously announced review and evaluation of strategic alternatives. As previously disclosed on November 30, 2022, Titan's Board of Directors determined that it was in the best interests of the Company and its stakeholders to undertake a review and evaluation of strategic alternatives and engaged Raymond James as the Company's financial advisor. At the direction of the Board, Titan's financial advisor and members of Titan's leadership team conducted a comprehensive outreach to over 40 potential counterparties, engaged in a number of management p

    2/8/23 9:15:00 AM ET
    $TMDI

    $TMDI
    SEC Filings

    View All

    SEC Form 15-15D filed by Titan Medical Inc.

    15-15D - TITAN MEDICAL INC (0000840551) (Filer)

    4/19/23 3:50:36 PM ET
    $TMDI

    SEC Form EFFECT filed by Titan Medical Inc.

    EFFECT - TITAN MEDICAL INC (0000840551) (Filer)

    4/11/23 12:15:04 AM ET
    $TMDI

    SEC Form EFFECT filed by Titan Medical Inc.

    EFFECT - TITAN MEDICAL INC (0000840551) (Filer)

    4/11/23 12:15:16 AM ET
    $TMDI

    $TMDI
    Leadership Updates

    Live Leadership Updates

    View All

    Titan Medical Announces Appointment of Eric Heinz as Vice President, Market and Corporate Development

    TORONTO, ON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. ((Nasdaq: TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that Eric Heinz has been appointed as the company's Vice President, Market and Corporate Development. Mr. Heinz will be responsible for developing and executing on strategic business plans to expand and accelerate Titan's Enos™ robotic single access surgical system's portfolio cadence. He will also lead existing partnerships and look to supplement those to maximize Titan's reach and the utilization of the Enos system. Mr. Hei

    9/26/22 7:30:00 AM ET
    $TMDI

    Titan Medical Announces Appointment of Cary G. Vance as President and Chief Executive Officer

    TORONTO, June 30, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. ((Nasdaq: TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that Cary G. Vance has been appointed as the company's President and CEO effective July 1, 2022. Mr. Vance will succeed Paul Cataford, Titan's chair of the board of directors, who has served as Interim President and CEO since December 2021. Mr. Vance previously served as President and CEO at Xcath Incorporated, a privately held neurovascular robotics company, and held similar positions at Optiscan Biomedical, and Myoscience. He a

    6/30/22 4:01:00 PM ET
    $TMDI

    Titan Medical Reports Voting Results From Annual and Special Meeting of Shareholders

    TORONTO, June 09, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. ((Nasdaq: TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced the voting results form the company's Annual and Special Meeting of its shareholders held on Wednesday June 8, 2022. All of management's nominees for election were duly elected as directors of the company by the shareholders presented or represented by proxy at the meeting. A total of 54,760,905 of the 111,202,690 common shares outstanding, or 49.24%, were voted at the meeting. The results of the vote were reported to the meeting

    6/9/22 6:57:57 PM ET
    $TMDI

    $TMDI
    Financials

    Live finance-specific insights

    View All

    Titan Medical Reports Financial Results for the Third Quarter 2022, and Announces Special Shareholder Meeting

    TORONTO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three and nine months ended September 30, 2022. Additionally, the company announced that a special meeting of shareholders will be held virtually on January 12, 2023 to seek shareholder approval for a consolidation of its common shares, including for the purposes of demonstrating compliance with Nasdaq Rule 5550(a)(2). As previously shared, Nasdaq granted the company with an extension to regain compliance

    11/10/22 7:30:00 AM ET
    $TMDI

    Titan Medical Reports Financial Results for the Second Quarter 2022

    TORONTO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three and six months ended June 30, 2022. "I am thrilled to lead Titan Medical as President and CEO and have been committed to the company's mission to improve surgical outcomes as a director of the company since September 2020. We continue to make progress on impacting the future of minimally invasive robotic surgery and the operating room ecosystem. Our technical partnerships, our relationships with surg

    8/11/22 7:30:00 AM ET
    $TMDI

    Titan Medical Reports Financial Results for the First Quarter 2022

    Manufacturing Team and Capabilities Continue to Expand Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three months ended March 31, 2022. "The entire team is focused on driving performance and progress supporting our IDE application submission milestone. We are also starting to prepare for the forthcoming commercialization of the Enos single-access RAS platform for gynecological surgery, our initial target indication for use," stated Paul Cataford, Interim President, CEO and Board Chair. "We are

    5/12/22 7:30:00 AM ET
    $TMDI